Home» News&Events» News» Signing Ceremony Held for PKUHSC-Boehringer Ingelheim Joint Laboratory of Human Medicine

Signing Ceremony Held for PKUHSC-Boehringer Ingelheim Joint Laboratory of Human Medicine


  On the afternoon of May 21, 2024, the signing ceremony of PKUHSC-Boehringer Ingelheim Joint Laboratory of Human Medicine was held successfully.

  There has been a long history of cooperation between Boehringer Ingelheim and Peking University School of Public Health. Since the two sides signed a memorandum of cooperation in teaching and scientific research in 2014, the PKU doctoral students of epidemiology have been offered internship opportunity in Boehringer Ingelheim headquarters and China office each year. In terms of scientific research, the two sides have carried out cooperative research in the fields of skin diseases and infectious diseases. On the occasion of ten years of cooperation, the two sides set up a joint laboratory, which will deepen the existing cooperation in more disease fields, promote the transformation of production, learning and research, and benefit patients in China and around the world.


  The joint laboratory implements the director responsibility system under the guidance of the academic committee. The director is Professor Zhan Siyan, and the director of the academic committee is Professor Li Liming.

  The cooperation will focus on diseases with huge unmet needs, involving inflammatory immunity, tumors, heart-kidney-metabolism, ophthalmology, and emerging therapeutic fields. In addition to scientific research cooperation, the two sides will also enhance the cooperation in personnel training. In the future, the two sides will give full play to their respective resource advantages, focus on patients’ real dilemmas, produce high-quality evidence-based medical evidence through jointly exploring and carrying out real-world data research, help the research and development of innovative drugs while improving the overall level of drug research and development in China, and accelerate the benefit of more innovative drugs to Chinese patients.






  Written by: Lang Lang

  Edited by: Liu Xin

  Source: PKU School of Public Health